CannapharmaRx to Complete Additional Shipment in November

CannaPharmaRX, Inc. (OTC PINK:CPMD), a future leader in cutting-edge, highly efficient cannabis production, is pleased to announce continued progress at its Cremona, Alberta facility, where cannabis cultivation remains on track according to the company’s annual plan. Following the resignation of CEO Dean Medwid in early September, the company has been able to maintain uninterrupted operations while fulfilling and delivering its orders

Recent Shipments to Israel
CannaPharmaRx has completed two shipments of its products to purchasers in Israel. A third shipment of approximately 300 kg is currently in the final stages of preparation and is expected to be dispatched in the near term. The average price for the third shipment is projected at CAD 2.10 per gram, with final pricing based on batch quality and THC results.

Additionally, an order for a shipment of 250 kg of company product to Israel has been received and is scheduled for delivery during the current quarter.
The company anticipates a regular cadence of orders and shipments during 2025 resulting in significant revenue growth next year.

Following the successful launch of the company’s products in Israel, CannaPharmaRx is in preliminary discussions with companies in Europe and elsewhere internationally to increase the distribution of our products and to establish a global presence.

Cautionary Note Regarding Forward-Looking Information or Statements

This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are ‘forward-looking information or statements.’ Forward-looking information or statements can be identified by the use of words such as ‘plans,’ ‘expects,’ or ‘does not expect,’ ‘is expected,’ ‘estimates,’ ‘intends,’ ‘anticipates,’ or ‘does not anticipate,’ or ‘believes,’ or variations of such words and phrases or statements that certain actions, events or results ‘may,’ ‘could,’ ‘would,’ ‘might’ or ‘will’ be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.

View the original press release on accesswire.com